Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2013OC127 Principal Investigator Tolar, Jakub
Phase NA
Age Group Both Scope Local
Secondary Protocol No. MT2013-34C
Title MT2013-34C: Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia: Standard of Care Considerations
Objective ENDPOINTS Specific transplant related endpoints include incidence of: • neutrophil engraftment at day 42 and platelet engraftment at 1 year • regimen related morality at 100 days • acute GVHD at 100 days • chronic GVHD at 6 months and 1 year • secondary malignancies
Applicable Disease Sites Other Hematopoietic
Therapies Involved Blood and Marrow Transplant
Drugs Involved Alemtuzumab (Campath)
Anti-Thymocyte Globulin - Rabbit (ATG)
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
FLUDARABINE (FLUDARA)
Total Body irradiation (TBI)
Status Open
Participating Institutions Masonic Cancer Center
Treatment Type Non-Cancer Therapeutic
Contact Cancer Information Line nurse Phone: 612-624-2620 - 1-888-226-2376
Email: ccinfo@umn.edu